This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignees: Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V. , Medical University of Vienna, Novartis Ag. Active years: 2001-2023.
Company Filing History:
1 out of 1,327 
1 out of 33 
1 out of 3,973 
Years Active: 2001-2023
Title: Georg Stingl: Innovator in Tuberculosis Detection and Allergy Research
Introduction
Georg Stingl is a notable inventor based in Vienna, Austria. He has made significant contributions to the fields of medical diagnostics and immunology. With a total of 2 patents, his work focuses on innovative methods for detecting latent tuberculosis infections and screening for allergy-related substances.
Latest Patents
Stingl's latest patents include a method for the detection of a latent tuberculosis infection (LTBI). This invention relates to an in vitro method that determines at least one nucleotide sequence and/or polypeptide of Mycobacterium tuberculosis (Mtb) in a blood cell population. The presence of these sequences or polypeptides indicates a latent tuberculosis infection. The method specifically enriches the blood cell population for hematopoietic stem cells. Additionally, he has developed a pharmaceutical composition for treating LTBI, which involves determining the presence of Mtb in the blood cell population. Another significant patent is an Elisa screening method for inhibitors of human IgE binding to the high-affinity receptor, FcεRIα. This invention allows for high-capacity screening of substances that interfere with the attachment of human IgE to its receptor, aiding in the differential analysis between autoimmune disorders and classical allergies.
Career Highlights
Throughout his career, Georg Stingl has worked with prominent organizations such as Novartis AG and the Max Planck Society for the Advancement of Science. His experience in these institutions has contributed to his expertise in medical research and innovation.
Collaborations
Stingl has collaborated with notable colleagues, including Julia Tornack and Stefan H. E. Kaufmann. These partnerships have further enhanced his research and development efforts in the medical field.
Conclusion
Georg Stingl's contributions to tuberculosis detection and allergy research highlight his innovative spirit and dedication to improving medical diagnostics. His patents reflect a commitment to advancing healthcare through scientific discovery.